Granulomatous Polyangiitis With Renal Involvement: A Case Report and Review of Literature

Thoyaja Koritala 1, Tuoyo O. Mene-Afejuku 1, Matthew Schaef er 2, Lavanya Dondapati 3, Yelena Pleshkova 4, Farah Yasmin 5, Hisham Ahmed Mushtaq 6, Anwar Khedr 6, 7, Ramesh Adhikari 8, 9, Abbas Al Mutair 10, Saad Alhumaid 11, Ali A. Rabaan 12, Jaffar A. Al-Tawfiq 13, Nitesh K. Jain 6, Syed Anjum Khan 6, Rahul Kashyap 14, Salim Surani 15, 16, 17, 18, 19

Abstract

Granulomatosis with polyangiitis (GPA), formerly named Wegner’s granulomatosis is an antineutrophil cytoplasmatic antibody (ANCA) associated vasculitis of the small vessels. GPA can affect several organ systems even though predominantly affects respiratory and renal systems. Pathogenesis is initiated by activation of the immune system to produce ANCA, Cytoplasmatic (C-ANCA) antibody, which thereby leads to widespread necrosis and granulomatous inflammation. Multisystem involvement with varied symptomatology makes GPA diagnosis more challenging. Early diagnosis and management are vital and can alter the prognosis of the disease. We present a literature review and a clinical scenario of a 26-year-old male with a history of chronic sinusitis, testicular carcinoma in remission, recent onset of worsening cough, epistaxis, hoarseness of voice, weight loss, and dark-colored urine. Workup revealed high titers of C-ANCA, C-reactive protein, procalcitonin, CT chest evidence of mass-like consolidation, and bronchoscopy findings of friable tissue that was not amenable for biopsy. Methylprednisolone and rituximab (RTX) were administered, which resulted in marked clinical improvement. Therefore, a keen eye for details is necessary to diagnose GPA early, which can improve disease outcomes dramatically.

Categories: Internal Medicine, Nephrology, Pulmonology
Keywords: wegener’s granulomatosis, wheezing, weight loss, pulmonary cavitation, hemoptysis, chronic sinusitis

Introduction

The three subtypes of antineutrophil cytoplasmatic antibody (ANCA) associated vasculitides are microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Among the three, GPA is the most common [1]. GPA, previously named Wegener’s granulomatosis, is a small-medium vessel disease characterized by necrotizing and granulomatous vasculitis that affects predominantly the respiratory tract as well as the kidney [1]. GPA comprises a triad of (a) upper respiratory tract (sinusitis, crusting rhinitis, saddle nose deformity, mastoiditis, hearing loss, otitis media) and lower respiratory tract (lung nodules, alveolar hemorrhage), (b) systemic (pauci-immune) vasculitis, and (c) renal involvement (glomerulonephritis) [2]. The global incidence of GPA is estimated to be 10-20 cases per one million annually, depending upon the geographical location [2]. A higher incidence is noted in the colder climatic areas [2,3]. The incidence rate in the United States is 12.8 cases/million person-years in working-age adults and 1.8 cases/million person-years in children [3]. GPA is generally seen in the geriatric population with a peak at 64-75 years of age, and recent studies demonstrated no gender preference or predisposition [4]. Even though the peak incidence is among older individuals, it may still present in the younger individuals and therefore posing a great diagnostic challenge as it was in this case presentation. GPA is commonly documented in Whites, although it is noted in all racial and ethnic groups [2].

We report an interesting case of a young man with multiple chronic medical problems who presented to the ER with life-threatening symptoms in whom a high index of suspicion triggered an early diagnosis of GPA, resulting in a prompt therapy leading to excellent clinical outcomes.
The diagnosis of GPA is very intriguing because it mimics many other disease processes. Undiagnosed GPA may have devastating consequences. Prompt diagnosis and therapy, on the other hand, may alter the grim prognosis of this disease which is regarded as a great masquerader. In fact, early therapy has been associated with survival rates as high as 83% in year one and 74% at five years [5,6].

Case Presentation

A 26-year-old male with a history of chronic sinusitis status post-surgery for nasal polyps and deviated septum (five years prior to presentation); prior nicotine dependence, psoriasis, and testicular cancer status post-surgery and chemotherapy (two years prior to presentation) currently in remission presented to the hospital because of acute worsening of chronic cough and shortness of breath. His presentation to our hospital’s ER was preceded by a clinic visit for chronic sinusitis, where he was prescribed a 10-day course of oral amoxicillin/clavulanate at that time. He had also been previously evaluated by the otorhinolaryngologist a few months back, who did a CT scan of the sinuses that revealed chronic pansinusitis. He was being prepped for more surgeries (debridement) for the sinus problems when he had progressive worsening of shortness of breath.

At the time he presented to our ER, he was short of breath at rest and had an audible wheeze. He had a cough productive of blood-tinged sputum, pleuritic chest pain, and right-sided neck pain. He had associated night sweats and weight loss (lost approximately 25 lbs. in the last two months). Positive history of chronic nasal congestion, impaired hearing, and epistaxis was noted. He also had new-onset hoarseness of voice and passage of dark-colored urine. He denied contact with persons with chronic cough or residence in areas noted to be endemic for tuberculosis. He was using adalimumab once monthly for plaque psoriasis of the knee, with the last dose taken a month prior to the presentation. He denied having nausea, vomiting, diarrhea, rashes, lower extremity swelling, orthopnea, or dysuria. Vitals were significant for temperature 37.1°C, pulse 108/min, respiratory rate 20 /min, blood pressure 128/79 mmHg, and oxygen saturation at 88% on room air, which improved to 98% after the administration of two liters of oxygen via nasal cannula.

Laboratory workups were notable for worsening normocytic anemia with hemoglobin of 9.1 g/dl, white blood cell count of 14,100/µL with neutrophil predominance, platelet count elevated to 639,000/µL, C-reactive protein (CRP) 242 mg/L (reference range, <=8 mg/L), albumin 3.2 g/dl, procalcitonin 0.18 ng/ml (reference range, <=0.08 ng/ml), and hemoglobin A1c 6.0%. Urinalysis revealed blood, dysmorphic red cells, and protein. Infectious workup was negative for bacteremia, methicillin-resistant Staphylococcus aureus nasal screen, legionella, and Streptococcus pneumoniae urine antigens, serology of Aspergillus, Blastomyces, and Cryptococcus, Pneumocystis jiroveci pneumonia, Mycobacterium tuberculosis, HIV, influenza A/B, respiratory syncytial virus, and COVID-19 infections. He had a chest x-ray that revealed multifocal bilateral nodular appearing airspace opacities (Figure 1).
FIGURE 1: A chest radiograph anteroposterior view showing multifocal bilateral nodular airspace opacities (arrows).

He also had a chest CT angiogram for better characterization of the lesions seen on the chest x-ray. The chest CT (Figure 2) revealed scattered areas of mass-like consolidation in a predominantly peri-hilar and peripheral distribution within the lungs. Some areas appeared to have early cavitation.
Vasculitis was considered as the top differential because of the constellation of chronic sinusitis, normocytic normochromic anemia, thrombocytosis, cavitary lung lesions, hemoptysis, asthma-like symptoms, hoarse voice, hematuria, and hearing loss. The results of the antinuclear antibody test (ANA) came back negative, but C-ANCA was positive 1:512 (reference range: negative), and proteinase three antibodies > 8 units/ml (reference range <0.4 units/ml) were elevated. He underwent bronchoscopy to confirm the diagnosis of GPA and to further evaluate for any infection. Biopsy was not obtained during bronchoscopy due to the friability of the tissue. Nephrology did not recommend kidney biopsy, given urinalysis being consistent with kidney involvement. He was started on pulse dose steroids of 1g methylprednisolone for three days with subsequent tapering doses of oral prednisone along with *Pneumocystis jiroveci* prophylaxis with trimethoprim-sulfamethoxazole and calcium and vitamin D supplementation. He continued saline nasal rinses every hour as recommended by an otorhinolaryngologist. He was also started on rituximab (RTX) 375 mg per m2 per week for four weeks after negative chronic hepatitis panel results were obtained. Figure 3 details the timeline of events and management in our patient.
He was recommended follow-ups with vasculitis clinic and otorhinolaryngology for subglottic stenosis in four to six weeks in the outpatient setting. Preventative vaccinations for COVID-19 upon discharge from the hospital were recommended due to the initiation of RTX. He was also advised to get the varicella vaccine (shingles), human papillomavirus vaccine (HPV), and pneumococcal vaccine. He had routine clinic follow-up as well as repeat bronchoscopies (two and three months after the index bronchoscopy), which revealed that the tracheal inflammation had much improved. The patient has been stable ever since.

Discussion

GPA is primarily characterized by a triad of necrotizing granulomatous inflammation of the upper and/or lower respiratory tract, necrotizing glomerulonephritis, and an autoimmune necrotizing systemic vasculitis affecting predominantly small vessels [7]. GPA primarily involves both the upper and lower respiratory tract and kidney. It can affect any organ in the body [8,9]. Infections like hepatitis B and C, drugs like hydralazine, and neoplasms are known to be associated with vasculitis. The pathogenesis of the disease is complex, ranging from an indolent disease involving only one site to fulminant, multiorgan vasculitis leading to death [8-10]. Most of the hallmark symptoms of the disease may be lacking initially but may evolve later. Cardinal histologic features on biopsy show widespread “geographic” necrosis and granulomatous inflammation [10]. ANCAs play a major role in the pathogenesis and often are associated with the activity of the disease [8-10]. The presence of ANCAs targeted against proteinase 3 (PR3-ANCA) is highly specific for Wegener’s granulomatosis. Myeloperoxidase (MPO)-ANCA or negative ANCA is seen in EGPA (Churg-Strauss syndrome) and MPA, which are the other two ANCA-associated vasculitides [11]. On biopsy, Wegener’s granulomatosis can be distinguished from its counterparts when the inflammatory infiltrates have a granulomatous pattern [12]. ANCA is detected only in approximately 50% of the patients with localized GPA (which is limited to the respiratory tract and affects about 5% of the patients), whereas PR3-ANCA antibodies are detected in 95% of the patients with generalized GPA [10-13].

Clinical features

Clinical manifestations of GPA are protean; GPA can affect almost any organ.

Upper Airway Manifestations

More than 85% of the patients with GPA often present with upper respiratory tract symptoms that include chronic sinusitis, epistaxis, or otitis media [7,8,14-16] with abnormal findings in sinus CT scan, as seen in our patient [7,12]. Typical features include destruction of sinus bones (25-50%) and thickening or clouding of the sinuses (75%) [7,12]. Ear involvement presents in 30-50% of patients with GPA [7,12] and 20-30% of the patients will have hearing loss, otitis media, otitis externa, chronic mastoiditis [7,8,12]. The nasopharynx is affected in 60-80% of the patients with GPA [7,8,15]. Nasal congestion, bleeding, ulcers, septal perforation [7,16,17], and saddle nose deformity [7,8,15] may occur. Also, hoarseness or sore throat may reflect...
ulcerations or granulomatous involvement of the vocal cords or pharynx, as seen in our patient during his acute presentation for worsening shortness of breath [7].

**Pulmonary Manifestations**

GPA is the most common pulmonary vasculitides [12]. It most commonly affects lung parenchyma characterized by multiple nodules and masses, which is seen in 55-90% of GPA [6,18,19]. Symptoms include cough, dyspnea, impaired pulmonary function, bronchial stenosis, abnormalities on chest radiographs or CT scans, and diffuse alveolar hemorrhage (DAH) [6,18]. Chest imaging reveals lesions in 70% or more patients [7,19,20]. Characteristic findings are solitary or multiple nodules, cavitation, or infiltrates, as seen in our case presentation [7,19,20]. Other features of GPA include pleural effusions, tracheobronchial stenosis, septal bands, atelectasis, mass lesions, asymmetrical pleural thickening, and scarring [21-24]. Surgical lung biopsy (SLB) is ideal for diagnosing pulmonary GPA, which mostly reveals vasculitis and necrotizing granulomas [25,26]. Travis et al. [25] studied 87 open lung biopsies from 67 patients with pulmonary GPA, which reports the findings of vascular inflammation in 96%, parenchymal necrosis in 84%, dispersed giant cells in 79%, areas of geographic necrosis in 66%, granulomatous microabscesses with giant cells in 70%, and neutrophilic microabscesses in 65% of patients. Additionally, active GPA consists of focal infiltrate, consolidation, or ground-glass opacities [20-22]. Consolidation may reflect alveolar hemorrhage or granulomatous inflammation [27,28]. DAH secondary to a small vessel vasculitis may be the initial and only pulmonary manifestation of GPA [23].

**Renal Manifestations**

Glomerulonephritis (GN) is the most common renal pathology affecting 70 to 85% of GPA, but renal inadequacy considered as serum creatinine > 2.0 mg/dL involves only 10-15% of patients at presentation [6-8]. Usually, red cell casts, proteinuria, microscopic hematuria are seen prior to an increase in serum creatinine levels [6,7,12]. The typical renal lesion of GPA is a focal segmental GN without immune complexes, “pauci-immune GN.” [7,12]. Sometimes crescentic rapidly progressive glomerulonephritis (RPGN) is observed with the fulminating disease [12,27,28]. Granulomatous vasculitis is found in only 6-15% of renal GPA [6,7,12,28]. The disease onset and progression of renal involvement is variable, ranging from indolent (months to years) to fulminant or progressing to end-stage renal disease (ESRD) within days to weeks [27,28]. Dialysis-dependent ESRD develops in 10-33% of patients with GPA [7,12,28]. Extensive loss of glomeruli with crescentic or sclerotic features is seen in chronic dialysis-dependent renal failure biopsy specimens [27,28].

In a prospective study done by Andrassy et al. [29] to assess the survival and prognosis of 25 patients with biopsy-proven renal GPA, 14 patients ended up requiring dialysis at admission, four of whom went on to develop ESRD. Another prospective study by Gottenberg et al. [30] assessed the long-term outcome and prognosis among 37 patients with GPA and renal disease. During a period of 6.4 years, 15 out of 37 (41%) died, and two developed ESRD [30]. Similarly, Fauci et al. [6] conducted a prospective study in treating and closely studying 85 patients with well-documented Wegener’s granulomatosis over a 21-year period who died, and two developed ESRD [30]. The renal histopathology ranged from mild to severe glomerulonephritis with minimal urinary findings to fulminant diffuse necrotizing glomerulonephritis with proliferative and crescentic changes [6]. Extrarenal manifestations consistently precede renal disease in Wegener’s granulomatosis [6]. However, renal disease, once present, may progress from mild to severe glomerulonephritis within weeks and even days of its inception [6].

**Trachea and Bronchi Manifestations**

About 10-30% of patients with GPA develop tracheal or bronchial stenosis [7,12,31], where simultaneous involvement of the nasopharynx or sinuses is also seen [32]. Usually, 3-5 cm infra glottic region is affected, but a distal tracheobronchial tree can also be involved, which can occur even in mild disease [31-33]. Stenosis can be detected on bronchoscopy in the form of circumferential narrowing [32]. Biopsy findings of the trachea or bronchi are usually nonspecific [32-33]. Thin-section CT helps in the assessment of the depth of tissue spread [34-36]. MRI and laryngoscopy provide comparable results for grading of subglottic stenosis in GPA and correlate well with pulmonary function testing [36].

**Ocular Manifestations**

Ocular symptoms are seen in 20-50% of patients with GPA [7,8,37]. Pathogenesis involves the spread of the granulomatous inflammation from the adjacent soft tissues or sinuses into the orbit or due to primary vasculitis of the retinal blood vessels [38]. About 15-20% of patients with GPA develop conjunctivitis, episcleritis, and scleritis [6,39]. Rare complications are optic neuritis, necrotizing keratitis, posterior uveitis, corneoscleral perforation [59]. Corticosteroids are the mainstay of treatment, topical or systemic, depending on the severity. Immunosuppressive therapy is added for severe disease [6,39]. The involvement of optic
chiasm or orbit is treated by surgery [38,40].

Nervous System Manifestations

Nervous system spread, central or peripheral, is seen in less than 5% of GPA but can increase to 15–55% as the disease progresses [7,12,41]. Pathogenesis is related to vasculitis of the nervous tissues per se or contiguous spread of inflammation or granulomatous pathology affecting the spinal cord, meninges, and brain [42,43]. Most common are mononeuritis multiplex or polyneuritis comprising more than 50% pathology [42,43]. Other pathologies include stroke, cranial nerve palsies [42,43], diabetes insipidus (secondary to granulomatous involvement of the hypothalamus), focal deficits or seizures, altered mental status, or cognitive impairment, and pituitary insufficiency [44–46].

Joint Manifestations

Musculoskeletal pathology occurs in 30–50% of the patients manifesting as arthralgia, arthritis, and myalgia [47]. Knee and ankles are more commonly affected [48]. Often musculoskeletal GPA can be misdiagnosed as rheumatoid arthritis (RA), where cyclic citrullinated peptide (CCP) antibody is measured to differentiate both the diseases [49].

Cardiac Manifestations

Cardiac involvement is rare, but prevalence rates of 3.3–15% have been estimated [50]. Pericarditis and coronary arteritis are the most common pathology [51]. Complications include heart failure, arrhythmias, or cardiomyopathy [51,52]. Echocardiography, especially transesophageal echocardiography, can easily identify and delineate cardiac, proximal aortic involvement and may also be used to assess response to treatment [50].

Treatment

New concepts are evolving to treat GPA. Corticosteroids and cyclophosphamide (CYC) have been the cornerstone for the management of generalized, multisystemic GPA since the 1970s [6]. Later, recent advances in the treatment proved the efficacy of RTX, a monoclonal antibody directed against B cells. Moreover, RTX use is beneficial for avoiding the side effects caused by CYC, inducing remission, and decreasing relapse rates [12]. This was the mainstay of therapy in our patient, and this appeared to have been associated with good clinical response.

RTX, methotrexate, mycophenolate, and azathioprine are used to maintain remission of GPA. For patients with GPA without renal involvement, corticosteroids along with weekly oral methotrexate of 20–25 mg are utilized instead of RTX or CYC [53]. Mycophenolate mofetil is used for treating patients who have GPA relapses or inadequate response despite receiving therapy with CYC and/or RTX. Patients who are intolerant of CYC or RTX can be treated with mycophenolate, azathioprine, or methotrexate [54]. In patients with life-threatening illnesses, concurrent therapy with RTX and CYC is initiated to circumvent the poor prognosis. Patients on high-dose corticosteroid therapy should have pneumocystis prophylaxis, blood glucose monitoring, bone density assessment, and supplemental vitamin D, and calcium as needed. Since infection in the first year of therapy is associated with mortality and morbidity, annual influenza and pneumococcal vaccines are recommended, along with tuberculosis and hepatitis B screening. Given the multisystem involvement, our patient was treated with methylprednisolone and RTX with the intent of inducing remission. As he was discharged on prolonged steroid taper, pneumocystis prophylaxis with trimethoprim-sulfamethoxazole, insulin for glycemic control, calcium, and vitamin D supplements were recommended along with COVID-19, varicella, pneumococcal, and HPV vaccines. Multidisciplinary care, as in our patient, is warranted in the outpatient setting to ensure optimal recovery and maintenance of remission.

Conclusions

GPA very frequently can be missed due to its varied and misleading symptomatology, contributing to delayed treatment often leading to poor clinical outcomes. GPA should be considered as a diagnosis when the presentation involves multiple systems, including joints, kidneys, and lungs. In cases where patients present with atypical symptoms and signs, it would be beneficial to include immunological testing such as the ANCA test to accurately diagnose GPA. Early diagnosis of GPA is very crucial for providing the right treatment in such cases. Lifesaving treatment of GPA is based on prompt and aggressive administration of pulse steroids, and RTX may improve outcomes.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Mayo Clinic, Mankato issued approval NA. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support
was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Vera-Lastra O, Olivera-Acevedo A, McDonal-Verza A, Pachec-Ruelas M, Gayosso-Rivera JA: Wegener’s granulomatosis: diagnosis and treatment [Article in Spanish]. Gac Mex Med. 2009, 145:121-9.

2. Natsaki E, Watts RA, Scott DG: Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010, 36:347-61.

3. Panugattanapong S, Sivalley DL, White AJ, Olsen MA, French AR, Hartman ME: Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large national claims database. Arthritis Rheumatol. 2018, 70:2067-76. 10.1002/art.40577

4. Garlapati P, Quire A: Granulomatosis with Polyangiitis. StatParses Publishing, Treasure Island, FL; 2021.

5. Takala JH, Kautiainen H, Leirisalo-Repo M: Survival of patients with Wegener’s granulomatosis diagnosed in Finland in 1981-2000. Scand J Rheumatol. 2010, 39:51-6. 10.5109/0300974095140701

6. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983, 98:76-85. 10.7262/0003-4819-98-1-76

7. Burkhardt O, Kiblenstein T, Wrenger E, Lux A, Neumann KH, Welte T: Predicting outcome and survival in patients with Wegener’s granulomatosis treated on the intensive care unit. Scand J Rheumatol. 2007, 36:119-24. 10.1080/0300974070611

8. Hoffman GS, Kerr GS, Leavitt RY, et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992, 116:488-98. 10.7262/0003-4819-116-6-488

9. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL: An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000, 43:1021-52. 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J

10. Abdou NI, Kullman GI, Hoffman GS, et al.: Wegener’s granulomatosis: survey of 701 patients in the United States. Changes in outcome in the 1990s. J Rheumatol. 2002, 29:399-16.

11. Travis WD: Pathology of pulmonary vasculitis. Semin Respir Crit Care Med. 2004, 25:475-82. 10.1055/s-2000-856141

12. Binda V, Moroni G, Mesa P: ANCA-associated vasculitis with renal involvement. J Nephrol. 2018, 31:197-208. 10.1007/s40620-017-0412-z

13. Lynch JP 3rd, Derhovanessian A, Tazelaar H, Belperio JA: CT findings in Wegener’s granulomatosis: evolving concepts in treatment. Semin Respir Crit Care Med. 2018, 39:434-58. 10.1055/s-0038-1660874

14. Lampecht P, Gross WL: Wegener’s granulomatosis. Herz. 2004, 29:47-56. 10.1007/s00599-004-2525-0

15. Gubbels SP, Barkhuizen A, Hwang PH: Head and neck manifestations of Wegener’s granulomatosis. Otolaryngol Clin North Am. 2005, 36:685-705. 10.1016/s0030-6665(05)00025-9

16. Cannady SB, Batra PS, Koenig C, Lorenz RR, Citardi MJ, Langford C, Hoffman GS: Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope. 2009, 119:757-61. 10.1200/lary.2011

17. Langford CA, Hoffman GS: Rare diseases 3: Wegener’s granulomatosis. Thorax. 1999, 54:629-37. 10.1136/thx.54.7.629

18. Rasmussen N: Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist’s perspective. Curr Opin Rheumatol. 2001, 13:5-11. 10.1097/00002281-200101000-00002

19. Cartín-Ceba R, Peikert T, Specks U: Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep. 2012, 14:481-93. 10.1007/s11926-012-0286-y

20. Flint J, Morgan MD, Savage CO: Pathogenesis of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010, 36:463-77.

21. Shin MS, Young KR, Ho KJ: Wegener’s granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration. Clin Imaging. 1998, 22:99-104. 10.1016/s0899-7071(97)00057-2

22. Reuter M, Schnabel A, Wesner F, Tetzlaff K, Risbjerg Y, Gross WL, Heller M: Pulmonary Wegener’s granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest. 1998, 114:500-6. 10.1378/chest.114.2.500

23. Sheehan RE, Flint JD, Müller NL: Computed tomography features of the thoracic manifestations of Wegener granulomatosis. J Thorac Imaging. 2003, 18:54-41. 10.1097/00002281-200305000-00005

24. Yoshimura N, Matsubara O, Yamada A, Kasuga T, Mark EJ: Wegener’s granulomatosis. Associated with diffuse pulmonary hemorrhage. Acta Pathol Jpn. 1992, 42:657-61. 10.1111/j.1440-1827.1992.tb05047.x

25. Lee KS, Kim TS, Fujimoto K, et al.: Thoracic manifestation of Wegener’s granulomatosis: CT findings in 30 patients. Eur Radiol. 2003, 13:43-51. 10.1007/s00350-002-1422-2

26. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS: Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol. 1991, 15:315-33. 10.1097/00000478-199104000-00001

27. Carruthers DM, Connor S, Howie AJ, Esley AR, Raza K, Bacon PA, Guest P: Percutaneous image-guided biopsy of lung nodules in the assessment of disease activity in Wegener’s granulomatosis. Rheumatology (Oxford). 2000, 39:776-82. 10.1093/rheumatology/39.7.776

28. Quartuccio L, Bond M, Isola M, et al.: Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. J Autoimmun. 2020, 108:102397. 10.1016/j.jaut.2019.102397
29. Aasand K, Bostad L, Hamrestrøm J, Jørstad S, Iversen BM: Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant. 2001, 16:953-60. 10.1093/ndt/16.5.953
30. Andrassy K, Ehr A, Koderich J, Waldberr R, Ritz E: Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol. 1991, 35:159-47.
31. Gottenberg JE, Mahr A, Pagnoux C, Cohen P, Mouton L, Guillon L: Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. Presse Med. 2007, 36:771-8. 10.1016/j.lpm.2006.11.025
32. Gluth MB, Shinniers PA, Kasperbauer JL: Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope. 2005, 113:1304-7. 10.1002/lary.20510
33. Langford CA, Snell MC, Hallahan CW, et al.: Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum. 1996, 39:1754-60. 10.1002/art.1780391020
34. Screaton NJ, Sivasothy P, Flower CD, Lockwood CM: Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT. Clin Radiol. 1998, 53:809-15. 10.1016/s0003-9866(98)80191-8
35. Boiselle PM, Reynolds RF, Ernst A: Multiplanar and three-dimensional imaging of the central airways with multidetector CT. AJR Am J Roentgenol. 2002, 179:501-8. 10.2214/ajr.179.2.1790501
36. Hennes FO, Lautien M, Linsenhoff L, et al.: Accuracy of magnetic resonance imaging for grading of subglottic stenosis in patients with granulomatosis with polyangiitis: correlation with pulmonary function tests and laryngoscopy. Arthritis Care Res (Hoboken). 2018, 70:777-84. 10.1002/acr.23532
37. Newman NJ, Slamovits TL, Friedland S, Wilson WB: Neuro-ophthalmic manifestations of meningoencephalitis from the limited form of Wegener's granulomatosis. Am J Ophthalmol. 1995, 120:613-21. 10.1016/s0002-9394(14)72208-1
38. Valmaggia C, Neuweiler I: Orbital involvement as the first manifestation in classic Wegener's granulomatosis. Orbit. 2001, 20:231-7. 10.1076/orbi.20.3.231.2618
39. Haynes BF, Fishman MI, Faucci AS, Wolff SM:_index]. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med. 1977, 63:131-41. 10.1002/1095-9343%57%950225-5
40. Pakrou N, Selva D, Leibovitch I: Wegener's granulomatosis: ophthalmic manifestations and management. Sem Arthritis Rheum. 2006, 35:284-92. 10.1016/s0002-928x(05)00231-0
41. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE: Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1995, 33:4-9. 10.1002/ana.410330103
42. Graf J: Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am. 2017, 43:573-8. 10.1016/j.rheum.2017.02.002
43. Holle JU, Grins WL: Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol. 2011, 23:7-11. 10.1097/BOR.0b013e32834115f9
44. Woywodt A, Knoblauch H, Kettritz R, Schneider W, Göbel U: Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis. Laryngoscope. 2017, 123:7-11. 10.1002/lary.26057
45. Valmaggia C, Neuweiler I: Orbital involvement as the first manifestation in classic Wegener's granulomatosis. Orbit. 2001, 20:231-7. 10.1076/orbi.20.3.231.2618
46. Haynes BF, Fishman MI, Faucci AS, Wolff SM: Index]. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med. 1977, 63:131-41. 10.1002/1095-9343%57%950225-5
47. De Parisot A, Puéchal X, Langrand C, et al.: Pituitary involvement in granulomatosis with polyangiitis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1995, 33:4-9. 10.1002/ana.410330103
48. Graf J: Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am. 2017, 43:573-8. 10.1016/j.rheum.2017.02.002
49. Holle JU, Grins WL: Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol. 2011, 23:7-11. 10.1097/BOR.0b013e32834115f9
50. Woywodt A, Knoblauch H, Kettritz R, Schneider W, Göbel U: Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis. Laryngoscope. 2017, 123:7-11. 10.1002/lary.26057
46. Haynes BF, Fishman MI, Faucci AS, Wolff SM: Index]. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med. 1977, 63:131-41. 10.1002/1095-9343%57%950225-5
51. McGeoch I, Carette S, Cuthbertson D, et al.: Cardiac Involvement in Granulomatosis with Polyangiitis. J Rheumatol. 2015, 42:1209-12. 10.3899/jrheum.141513
52. Cocco G, Gasparian AY: Myocardial ischemia in Wegener's granulomatosis: coronary atherosclerosis versus vasculitis. Open Cardiovasc Med J. 2010, 4:57-62. 10.2174/1874192401004020057
53. Shi L: Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017, 37:1779-88. 10.1007/s10029-017-3818-y
54. King C, Harper L: Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. Curr Treatm Opt Rheumatol. 2017, 3:230-43. 10.1007/s11954-017-0082-y